• menu
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.
    All News #Library
    Biotech

    Tang Returns As Aurinia CEO With $50M Offer After Kezar Buyout

    BIOSPACE

    French Biotech Pens $128M Deal For Kezar Protein Degrader Work

    FIERCE BIOTECH

    Kezar Updates on Zetomipzomib for Autoimmune Hepatitis

    PHARMIWEB

    Kezar Life Sciences Reports Third Quarter 2025 Financial Results

    BUSINESSWIRE

    Kezar Life Sciences Presents PORTOLA Data at AASLD Liver Meeting

    BUSINESSWIRE

    Kezar Plans Layoffs After FDA Axes Meeting To Discuss Next Trial

    FIERCE BIOTECH

    Kezar Updates Zetomipzomib Program, Explores Strategic Options

    PHARMIWEB

    Kezar Life Sciences to Present at Two Investor Conferences

    BUSINESSWIRE

    Kezar Life Sciences Q2 2025 Financial Results and Update

    BUSINESSWIRE

    Kezar Resumes Lupus Program After Hepatitis Hold Lifted

    FIERCE BIOTECH

    Kezar Life Sciences: FDA Lifts Partial Hold on PORTOLA Trial

    BUSINESSWIRE

    Kezar Life Sciences Reports Q1 2025 Results and Business Update

    BUSINESSWIRE

    Kezar Life Reports Positive Results from PORTOLA Ph 2 Trial

    BUSINESSWIRE

    Kezar Life Sciences to Present PORTOLA Phase 2a Trial Results

    BUSINESSWIRE

    Kezar To Present Zetomipzomib Data In AIH, Lupus Trial Update

    BUSINESSWIRE

    Kezar Life Sciences Reports Q3 2024 Financial Results & Update

    BUSINESSWIRE

    Kezar Life Sciences Announces 1-for-10 Reverse Stock Split

    BUSINESSWIRE

    Kezar Cuts Lupus Program, Focuses on Autoimmune Hepatitis

    BIOSPACE

    Kezar Life Sciences Reports Positive Portola Trial Safety Review

    BUSINESSWIRE

    Kezar rejects Concentra buyout that `undervalues` the biotech

    FIERCE BIOTECH

    Kezar halts mid-stage lupus study after four deaths

    FIERCE BIOTECH

    Kezar Life Sciences Ends Enrollment In Ph2 Trial For Zetomipzomib

    BUSINESSWIRE

    Kezar Life Sciences Reports Q2 2024 Results And Business Update

    BUSINESSWIRE

    Kezar and Everest Medicines Enter into an Agreement to Develop Zetomipzomib

    BUSINESSWIRE

    Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.